Security key
501575104
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)
CUSIP: 501575104
Q2 2023 13F Holders as of 30 Jun 2023
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 58,230,116
- Total 13F value
- $1,338,678,295
- Share change
- +1,560,147
- Put/Call ratio
- 46%
- SEC-reported price per share
- $22.99
- Number of holders
- 124
- Value change
- +$29,100,921
- Number of buys
- 66
- Number of sells
- 48
- Shares outstanding
- 81,496,373
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q2 2023
Institutions
124
Top holders
10
KYMR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 501575104
Recent filing periods:
Ownership snapshot
Top reported holders of KYMR - Kymera Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Life Scienc...
Disclosed value leader
Atlas Venture Life Scienc...
Comparable rows
15/15
Latest evidence
31 Mar 2023
13F
Lead comparable stake: 7.2%
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Life Science Advisors, LLC leads the comparable SEC ownership view at 7.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Atlas Venture Life Science Adviso...
7.2%
BVF INC/IL
5.8%
PRICE T ROWE ASSOCIATES INC /MD/
5.7%
WELLINGTON MANAGEMENT GROUP LLP
5.3%
Avoro Capital Advisors LLC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
7.2%
|
$173,580,303
5,858,262 shares
|
— | 31 Mar 2023 |
| BVF INC/IL |
13F
Company
|
5.8%
|
$140,416,689
4,739,004 shares
|
— | 31 Mar 2023 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
5.7%
|
$138,275,000
4,666,681 shares
|
— | 31 Mar 2023 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
5.3%
|
$127,142,862
4,291,018 shares
|
— | 31 Mar 2023 |
| Avoro Capital Advisors LLC |
13F
Company
|
4.7%
|
$114,223,650
3,855,000 shares
|
— | 31 Mar 2023 |
| VANGUARD GROUP INC |
13F
Company
|
4.6%
|
$110,636,198
3,733,925 shares
|
— | 31 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
124
Shares
58,230,116
Rows available
124
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
123
Q2 2023 holders
124
Holder diff
1
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q2 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend